OrbusNeich Medical Group Holdings Limited (HKG:6929)
3.770
-0.100 (-2.58%)
Jan 21, 2026, 3:00 PM HKT
HKG:6929 Revenue
OrbusNeich Medical Group Holdings had revenue of $83.55M USD in the half year ending June 30, 2025, with 2.63% growth. This brings the company's revenue in the last twelve months to $168.74M, up 11.48% year-over-year. In the year 2024, OrbusNeich Medical Group Holdings had annual revenue of $164.10M with 6.65% growth.
Revenue (ttm)
$168.74M
Revenue Growth
+11.48%
P/S Ratio
2.41
Revenue / Employee
$126.77K
Employees
1,331
Market Cap
3.19B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 164.10M | 10.23M | 6.65% |
| Dec 31, 2023 | 153.87M | 17.04M | 12.45% |
| Dec 31, 2022 | 136.82M | 20.36M | 17.48% |
| Dec 31, 2021 | 116.46M | 27.99M | 31.64% |
| Dec 31, 2020 | 88.47M | -7.87M | -8.17% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 38.69B |
| Alibaba Health Information Technology | 36.09B |
| Sino Biopharmaceutical | 33.49B |
| CSPC Pharmaceutical Group | 28.65B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |